Innovega
Steve Willey is the Co-Founder, President and CEO of Innovega. Steve has been with the company since it's inception in 2007 and has been instrumental in it's success.
Prior to Innovega, Steve was the President, CEO and Director of TSE Public Company & Telematics Pioneer from September 2007 to January 2010. Steve was responsible for innovating telematics products for enterprise and consumers. Steve is also a Qualcomm licensee.
From June 1993 to August 2007, Steve was the Co-founder, President and Director of NASDAQ listed Microvision inc. Steve was responsible for innovating the company's laser-based PicoProjector, a high-performance embedded component for mobile devices.
Steve's career began at Creo Products, Inc where they were the Director of Graphic Arts Products from January 1990 to January 1992. Steve was responsible for innovating electro-optic based, high-performance laser imaging products.
In December 1988, Steve co-founded Pro.Net, a WEB 1.0 and 2.0 Applications Development company where they served as President and Director until January 1990.
Steve's first foray into the tech industry was as the General Manager of MDI International Mobile Data from July 1979 to January 1983.
Steve Willey has an MBA from the UCLA Anderson School of Management, a M.A.Sc from the University of British Columbia in EE & Computer Graphics, and a B. Engineering Physics from McMaster University in Nuclear & Bio-Medical Engineering. Steve is also an Industrial Fellow at the Babson F.W. Olin Graduate School of Business in Entrepreneurship/Entrepreneurial Studies.
Bill Meyers - VP Materials & Lens Development, Peter Schuster - Director, Finance & Administration, and Jay Marsh - VP Engineering report to Steve Willey.
This person is not in any offices
Innovega
Innovega Inc. is developing stylish, lightweight, wearable displays that feature a high-resolution, panoramic-field-of-view system for medical, consumer, and industrial application. The Company is licensing its technology into the $74 billion global vision care market with a focus on image enhancement for the visually impaired. Its transformative patented platform, eMacula™, includes eyewear and iOptik® high-resolution smart contact lenses that work together to deliver broad application in medicine, augmented reality (AR), and virtual reality (VR). The Company has been supported by the Defense Advanced Research Projects Agency (DARPA), National Eye Institute (NEI) of National Institutes of Health (NIH), and National Science Foundation (NSF) and has received investments from strategic partners. The iOptik contact lens is in the FDA De Novo process Phase II clinical trials in progress. The Company is also pursuing FDA 510(k) Clearance for its lens material.